Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mycophenolate mofetil
Drug ID BADD_D01507
Description Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).[A180805] This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants.[L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995.[A180826] In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over carcinogenicity.[A180826] The new semi-synthetic 2-morpholinoethyl ester of MPA was synthesized to avoid the gastrointestinal effects associated with the administration of MPA. It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA.[A180826]
Indications and Usage For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
Marketing Status Prescription; Discontinued
ATC Code L04AA06
DrugBank ID DB00688
KEGG ID D00752
MeSH ID D009173
PubChem ID 5281078
TTD Drug ID D04FBR
NDC Product Code 0781-2067; 0904-7078; 70121-1584; 67877-230; 17478-422; 0093-7334; 71288-803; 70748-262; 70966-0015; 60429-070; 67877-266; 68254-0015; 69238-1595; 68254-2500; 51079-721; 16729-019; 68254-5000; 16714-345; 0378-4472; 65727-005; 17478-957; 66499-0006; 50090-2541; 55154-5382; 64380-725; 68382-669; 55486-1589; 0527-5160; 67877-225; 52972-0037; 72969-053; 78848-004; 0378-2250; 60429-059; 47848-019; 0004-0259; 0904-7074; 50090-4275; 70518-3068; 51079-379; 0004-0260; 0054-0166; 68254-0005; 64380-726; 68254-5003; 70748-186; 71052-317; 70518-2835; 0054-0163; 0004-0261; 70518-2767; 0781-5175; 42023-172; 60687-438; 70771-1084; 67457-386; 60687-494; 71610-033; 46014-1123; 65050-2101; 51927-5125; 66689-307; 16729-094; 55154-6262; 52076-6220
Synonyms Mycophenolic Acid | Mycophenolate Mofetil | Mofetil, Mycophenolate | Mycophenolic Acid Morpholinoethyl Ester | Cellcept | Mycophenolate Sodium | Sodium Mycophenolate | Mycophenolate, Sodium | Myfortic | Mycophenolate Mofetil Hydrochloride | Mofetil Hydrochloride, Mycophenolate | RS 61443 | RS-61443 | RS61443
Chemical Information
Molecular Formula C23H31NO7
CAS Registry Number 128794-94-5
SMILES CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Gastrointestinal perforation07.04.04.0010.000512%Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.002616%
Generalised tonic-clonic seizure17.12.01.0020.003269%Not Available
Gingival hyperplasia07.09.03.002--Not Available
Gingivitis11.01.04.013; 07.09.03.003--
Glomerular filtration rate decreased13.13.01.0090.001308%Not Available
Glomerulonephritis20.05.01.001; 10.02.01.0060.001962%Not Available
Glomerulonephritis membranous20.05.01.0070.001308%Not Available
Glossitis07.14.01.001--Not Available
Gout14.09.01.001; 15.01.06.001--Not Available
Graft versus host disease10.02.01.027; 12.02.09.0010.004094%Not Available
Granuloma23.03.15.001; 08.01.05.001--Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.0050.001308%
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematochezia24.07.02.012; 07.12.02.0030.001962%Not Available
Haematocrit decreased13.01.05.0010.001308%Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.0060.012424%
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.0030.007847%Not Available
Haemolysis01.06.04.002--
Haemolytic anaemia01.06.03.0020.001308%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.003923%
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.0060.002616%Not Available
Hallucination19.10.02.002--
Hallucination, visual19.10.02.0040.001962%Not Available
Headache17.14.01.001--
Heart disease congenital03.07.07.001; 02.01.01.0090.000341%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 28 Pages